Ten years of qualification
Audited Supplier
In This Store
Category:Active Pharmaceutical Ingredients > Cardiovascular System Drugs
Product Name:Clopidogrel Sulfate
CAS No.:120202-66-6
Standard:ChP, USP, BP, EP
Price(USD):1~11
Company:Arshine Group Co.,Ltd.
Grade: Pharmaceutical Grade
Factory Location: Block 14, No.100, Luyun Road, Changsha 410205, Hunan, China.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: L/C
Introduction: Welcome to the world of Clopidogrel Sulfate, a vital antiplatelet medication renowned for its role in preventing blood clot formation and safeguarding heart health. Clopidogrel Sulfate is a thienopyridine class drug that exerts its effects by inhibiting platelet activation and aggregation. This essential medication plays a crucial role in reducing the risk of cardiovascular events and supporting individuals with certain heart and vascular conditions. Let's explore the benefits and applications of Clopidogrel Sulfate in empowering heart health.
The Power of Clopidogrel Sulfate: Clopidogrel Sulfate is an antiplatelet agent that acts by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on platelets. By doing so, it prevents platelets from sticking together and forming clots, which are a common cause of heart attacks, strokes, and other cardiovascular complications. This action is particularly valuable in patients with a history of acute coronary syndrome, coronary artery stents, and other cardiovascular conditions.
Benefits of Clopidogrel Sulfate:
1:Cardiovascular Protection: Clopidogrel Sulfate is a cornerstone in the management of various cardiovascular conditions, providing protection against heart attacks, strokes, and unstable angina.
2:Post-Stent Placement Management: After coronary artery stent placement, Clopidogrel Sulfate is often prescribed to prevent stent thrombosis and support the long-term success of the procedure.
3:Peripheral Arterial Disease (PAD) Management: In individuals with PAD, Clopidogrel Sulfate can reduce the risk of blood clots in the peripheral arteries, improving blood flow and relieving symptoms.
4:Ischemic Stroke Prevention: Clopidogrel Sulfate is used in combination with aspirin for the prevention of recurrent ischemic strokes in certain patient populations.
5:Reduced Risk of Thrombotic Events: By inhibiting platelet activation, Clopidogrel Sulfate decreases the likelihood of thrombotic events in susceptible individuals, supporting overall cardiovascular well-being.
|
Product Name: |
Clopidogrel Bisulfate (CAS No.: 120202-66-6 ) |
||
|
Batch No.: |
C51-20220705 |
Quantity: |
200KG |
|
Manufacturing Date: |
Jun 14, 2022 |
Retest Date: |
Jun 13, 2024 |
|
Test Items |
Specifications |
Result |
|
Appearance |
White or almost white powder. |
Almost white powder |
|
Identification |
A. Corresponds to IR Spectrum of reference substance (EP 2.2.24) |
Conforms |
|
B. Enantiomeric purity ( HPLC,EP2.2.29) |
Conforms |
|
|
C. It gives reaction (a) of sulfate (EP2.3.1) |
Conforms |
|
|
Appearance of solution |
Clear (EP2.2.1) and not more intensely coloured than reference solution Y6 (EP2.2.2, method I) |
Conforms |
|
Specific optical rotation (EP2.2.7) |
+ 55.0° ~ +58.0° |
+57.3° |
|
Enantiomeric purity (HPLC,EP2.2.29) |
Impurity C≤0.5% |
0.002% |
|
Water (EP2.5.12) |
≤0.5% |
0.12% |
|
Sulfated ash (EP2.4.14) |
≤0.1% |
0.04% |
|
Related compounds (HPLC,EP2.2.29) |
Impurity A ≤ 0.2 % |
0.01% |
|
Impurity B≤0.3% |
0.05% |
|
|
Unspecified impurities≤O.10% |
0.06% |
|
|
Total impurities ≤0.5 % |
0.27% |
|
|
Assay (EP2.2.20) |
99.0%~101.0% Ci6H16C1NO2S H2SO4, calculated on anhydrous substance. |
99.4% |
|
Additional items (In-house) |
||
|
Residual solvents (GC,EP2.2.28) |
Methanol ≤0.3% |
0.0102% |
|
Acetone ≤ 0.5% |
0.1022% |
|
|
Methylene Chloride ≤0.06% |
0.0004% |
|
|
Isopropanol≤0.5% |
0.0080% |
|
|
Ethyl acetate≤0.5% |
ND |
|
|
Toluene≤0.089% |
|
|
|
Mesityl oxide≤0.1% |
0.0018% 1 |
|
|
Packaging and storage:Keep in an air-tight container, protected from light. |
||
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go
